Therapeutic Response

EGFR positive, Wild type HRAS, Wild type KRAS, and Wild type NRAS status confers therapeutic sensitivity to Cetuximab in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Erbitux (cetuximab) [product information]. EMA. The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.